Postoperative adjunctive bevacizumab versus placebo in primary trabeculectomy surgery for glaucoma | Zendy

Sana’ Muhsen | Zendy; Javiera Compan | Zendy; Tze Lai | Zendy; Christoph Kranemann | Zendy; Catherine M. Birt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Postoperative adjunctive bevacizumab versus placebo in primary trabeculectomy surgery for glaucoma

Author(s) -

Sana’ Muhsen,

Javiera Compan,

Tze Lai,

Christoph Kranemann,

Catherine M. Birt

Publication year - 2019

Publication title -

international journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 29

eISSN - 2227-4898

pISSN - 2222-3959

DOI - 10.18240/ijo.2019.10.08

Subject(s) - medicine , trabeculectomy , glaucoma , intraocular pressure , dry needling , bevacizumab , bleb (medicine) , ophthalmology , glaucoma surgery , placebo , surgery , chemotherapy , alternative medicine , pathology , acupuncture

To compare the effectiveness of postoperative adjunctive use of subconjunctival bevacizumab in altering the outcome of primary trabeculectomy in terms of sustained lowering of intraocular pressure (IOP) and reduction of postoperative bleb vascularization and fibrosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research